Future breast cancer care: ESMO Breast Cancer 2024
Transcript: Transforming HER2-positive breast cancer care: The FeDeriCa study
Professor Diana Lüftner
All transcripts are created from interview footage and directly reflect the content of the interview at the time. The content is that of the speaker and is not adjusted by Medthority.
The interesting thing of the FeDeriCa trial is that it is now an update from the paper that was presented or written down in "The Lancet" in 2021, if I recall it correctly. And FeDeriCa is comparing in short terms IV pertuzumab and trastuzumab in the early setting, in the maintenance treatment, let me call it, for one year, versus subcutaneous administration with pertuzumab/trastuzumab. And the primary endpoint has been pharmacokinetic parameters that had shown that it is equivalent in terms of the serum concentrations that can be reached. What we've now seen is event-free survival data, so survival data, not only pharmacokinetic data, or PCR rates, but overall outcome data that were event equivalent. And this really supports the idea of using subcutaneous administration that is fast for patients and for healthcare personnel, and makes it so much easier. We have used pertuzumab/trastuzumab a lot in the pandemic, now where it was of a matter how long a patient is in the hospital, and how long he or she absorbs personnel that is necessary on other aspects because so many of us have been sick, or at least for some time. So it really supports the idea of saving time is good for the patient as well as for the hospital staff.
Updates in your area
of interest
of interest
Articles your peers
are looking at
are looking at
Bookmarks
saved
saved
Days to your
next event
next event
Developed independently by EPG Health, which received educational funding from Pierre Fabre Medicament awarded to EPG Health to help provide its healthcare professional members with access to the highest quality medical and scientific information, education and associated relevant content.